Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study by Lavery, A, Stevenson, L, McManus, D, Logan, GE, Walker, SM, Jellema, GL, Van Schaeybroeck, S, Virdee, PS, Middleton, MR, Elhussein, L, Turbitt, J, Colinson, D, Miedzybrodzka, Z, Petty, RD, Harkin, PD, Kennedy, RD, Eatock, MM, Thomas, AL, Turkington, RC

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma by Turkington, RC, Knight, LA, Blayney, JK, Secrier, M, Douglas, R, Parkes, EE, Sutton, EK, Stevenson, L, McManus, D, Halliday, S, McCavigan, AM, Logan, GE, Walker, SM, Steele, CJ, Perner, J, Bornschein, J, MacRae, S, Miremadi, A, McCarron, E, McQuaid, S, Arthur, K, James, JA, Eatock, MM, O'Neill, R, Noble, F, Underwood, TJ, Harkin, DP, Salto-Tellez, M, Fitzgerald, RC, Kennedy, RD, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group